Chemotherapy plus ponatinib: a new standard for Ph-positive ALL?

被引：3
|
作者：
Thomas, Xavier [1 ]
机构：
[1] Lyon Sud Hosp, Hosp Civils Lyon, Hematol, F-69495 Pierre Benite, France
来源：
LANCET ONCOLOGY | 2015年 / 16卷 / 15期
关键词：
ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; IMATINIB; RESISTANCE; INHIBITOR; PHASE-2;
D O I：
10.1016/S1470-2045(15)00247-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1451 / 1453
页数：4
相关论文
共 50 条
  • [21] MOLECULAR PATHOGENESIS OF PH-POSITIVE LEUKEMIAS
    CLARK, SS
    CRIST, WM
    WITTE, ON
    ANNUAL REVIEW OF MEDICINE, 1989, 40 : 113 - 122
  • [22] Should Ponatinib Be the Standard-of-Care Tyrosine Kinase Inhibitor in Ph+ ALL?
    Dabbour, Elias
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (09) : 413 - 415
  • [23] Ponatinib Versus Imatinib with Reduced-Intensity Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL): PhALLCON Study
    Jabbour, Elias
    Martinelli, Giovanni
    Vignetti, Marco
    Kantarjian, Hagop
    Gomez-Almaguer, David
    Minami, Yosuke
    Dombret, Herve
    Hennessy, Meliessa
    Vorog, Alexander
    Wang, Bingxia
    Ribera, Josep-Maria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S269 - S269
  • [24] SIGNIFICANCE OF MRD BY BCR-ABL QUANTITATIVE PCR DURINGCOMBINATION TREATMENT WITH VARIOUS TKIS PLUS CHEMOTHERAPY FOLLOWED BY ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PH-POSITIVE ADULT ALL
    Kim, D. Y.
    Lim, S. N.
    Joo, Y. D.
    Kim, S. D.
    Lee, J. H.
    Lee, J. H.
    Kim, D. H.
    Kim, K.
    Jung, C. W.
    Kim, I.
    Yoon, S. S.
    Park, S.
    Kim, B. K.
    Ahn, J. S.
    Yang, D. H.
    Lee, J. J.
    Kim, H. J.
    Kim, Y. S.
    Mun, Y. C.
    Kim, H.
    Moon, J. H.
    Sohn, S. K.
    Lee, W. S.
    Lee, S. M.
    Won, J. H.
    Hyun, M. S.
    Kim, M. K.
    Park, J.
    Lee, J. H.
    Shin, H. J.
    Eom, H. S.
    Lee, G. W.
    Ryoo, H. M.
    Bae, S. H.
    Cho, Y. U.
    Chi, H. S.
    Lee, K. H.
    HAEMATOLOGICA, 2014, 99 : 8 - 8
  • [25] A Phase II Study of the Sequential Combination of Low-Intensity Chemotherapy (mini-hyper-CVD) and Ponatinib Followed By Blinatumomab and Ponatinib in Patients with Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL)
    Nguyen, Daniel
    Jabbour, Elias
    Short, Nicholas
    Issa, Ghayas C.
    Yilmaz, Musa
    Daver, Naval
    Pemmaraju, Naveen
    Chien, Kelly S.
    Masarova, Lucia
    Ravandi, Farhad
    Jain, Nitin
    Deen, Wuliamatu
    Zhao, Min
    Loiselle, Christopher
    Waller, Lourdes
    Banks, Glenda
    Garris, Rebecca
    Kantarjian, Hagop
    BLOOD, 2022, 140 : 6127 - 6129
  • [26] INTENSIVE INDUCTION CHEMOTHERAPY FOR TDT NEGATIVE, NONLYMPHOID BLASTIC CRISES OF PH-POSITIVE CML
    ANGER, B
    HEIL, G
    BOHLKE, J
    SCHMEISER, T
    HEIMPEL, H
    BLUT, 1987, 55 (04): : 282 - 282
  • [27] Genomic analysis of two rare cases of pediatric Ph-positive T-ALL
    Sato-Otsubo, Aiko
    Osumi, Tomoo
    Yoshida, Masanori
    Iguchi, Akihiro
    Fukushima, Takashi
    Nakabayashi, Kazuhiko
    Ogawa, Seishi
    Hata, Kenichiro
    Kato, Motohiro
    PEDIATRIC BLOOD & CANCER, 2022, 69 (03)
  • [28] Safety and efficacy of glivec prior to allografting for CML and Ph-positive ALL: European experience
    Deininger, MWN
    Schleuning, M
    Olavarria, E
    Fischer, T
    Nagler, A
    Sayer, H
    Boque, C
    Volin, L
    Piotelli, G
    Russel, N
    Wandt, H
    Schanz, U
    Greinix, H
    Sponk, L
    Sponk
    Verdonck, L
    Lennard, A
    Wimmer, M
    Hegenbart, U
    Lange, T
    Niederwieser, D
    BONE MARROW TRANSPLANTATION, 2002, 29 : S31 - S31
  • [29] Is Initial Dasatinib-Blinatumomab Therapy for Ph-Positive ALL in Adults Cost Effective?
    Bitran, Jacob D.
    Nabrinsky, Edward
    Bufalino, Shams
    Knouse, Phillip
    Galvez, Angel G.
    BLOOD, 2021, 138
  • [30] Ponatinib superior to imatinib in Ph+ ALL
    Sidaway, Peter
    NATURE REVIEWS CLINICAL ONCOLOGY, 2024, 21 (07) : 483 - 483
12345